Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Overview

Journal ACS Infect Dis

Specialties Infectious Diseases
Microbiology
Pharmacology

Date 2020 Mar 4

PMID 32125140

Citations 165

Authors

Jimin Xu

Pei-Yong Shi

Hongmin Li

Jia Zhou

Affiliations

Soon will be listed here.

Abstract

The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.

Citing Articles

Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.

Comparison of Solid Self-Nanoemulsifying Systems and Surface-Coated Microspheres: Improving Oral Bioavailability of Niclosamide.

Baek K, Woo M, Din F, Choi Y, Kang M, Kim J Int J Nanomedicine. 2024; 19:13857-13874.

PMID: 39735329 PMC: 11681811. DOI: 10.2147/IJN.S494083.

Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity.

Liu Z, Liang X, Zhang Y, Deng W, Wang Y, Lu Z Infect Drug Resist. 2024; 17:4539-4556.

PMID: 39464831 PMC: 11505561. DOI: 10.2147/IDR.S490998.

Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition.

Cavina L, Bouma M, Girones D, Feiters M Molecules. 2024; 29(17).

PMID: 39274895 PMC: 11396989. DOI: 10.3390/molecules29174047.

Insight into Preventing Global Dengue Spread: Nanoengineered Niclosamide for Viral Infections.

Rejinold N, Jin G, Choy J Nano Lett. 2024; 24(46):14541-14551.

PMID: 39194045 PMC: 11583367. DOI: 10.1021/acs.nanolett.4c02845.

References

Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J . Zika Virus Associated with Microcephaly. N Engl J Med. 2016; 374(10):951-8. DOI: 10.1056/NEJMoa1600651. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Wang Y, Lu J, Lin C, Chin Y, Wu T, Lin L . Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res. 2016; 135:81-90. PMC: 7126800. DOI: 10.1016/j.antiviral.2016.10.003. View

Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58. DOI: 10.1038/nrd.2018.168. View

Luo D, Vasudevan S, Lescar J . The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Res. 2015; 118:148-58. DOI: 10.1016/j.antiviral.2015.03.014. View

Xu M, Lee E, Wen Z, Cheng Y, Huang W, Qian X . Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016; 22(10):1101-1107. PMC: 5386783. DOI: 10.1038/nm.4184. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Rasmussen S, Jamieson D, Honein M, Petersen L . Zika Virus and Birth Defects--Reviewing the Evidence for Causality. N Engl J Med. 2016; 374(20):1981-7. DOI: 10.1056/NEJMsr1604338. View

Kutok J, Wang F . Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol. 2007; 1:375-404. DOI: 10.1146/annurev.pathol.1.110304.100209. View

10.

Fan X, Xu J, Files M, Cirillo J, Endsley J, Zhou J . Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). Tuberculosis (Edinb). 2019; 116S:S28-S33. PMC: 7106448. DOI: 10.1016/j.tube.2019.04.008. View

11.

Huang L, Yang M, Yuan Y, Li X, Kuang E . Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation. Antiviral Res. 2016; 138:68-78. DOI: 10.1016/j.antiviral.2016.12.002. View

12.

Costabile G, dAngelo I, Rampioni G, Bondi R, Pompili B, Ascenzioni F . Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology. Mol Pharm. 2015; 12(8):2604-17. DOI: 10.1021/acs.molpharmaceut.5b00098. View

13.

Osada T, Chen M, Yang X, Spasojevic I, VanDeusen J, Hsu D . Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011; 71(12):4172-82. PMC: 3117125. DOI: 10.1158/0008-5472.CAN-10-3978. View

14.

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

15.

Fontes C, Dos Santos A, Marchiori E . Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection. Neuroradiology. 2016; 58(8):837-8. DOI: 10.1007/s00234-016-1687-9. View

16.

Sun Z, Zhang Y . Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis. 2000; 79(5):319-20. DOI: 10.1054/tuld.1999.0212. View

17.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

18.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

19.

Tao H, Zhang Y, Zeng X, Shulman G, Jin S . Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med. 2014; 20(11):1263-9. PMC: 4299950. DOI: 10.1038/nm.3699. View

20.

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View